StockNews.com Begins Coverage on Bio-Path (NASDAQ:BPTH)

Analysts at StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued on Thursday. The firm set a “sell” rating on the stock.

Bio-Path Stock Performance

NASDAQ:BPTH opened at $0.78 on Thursday. Bio-Path has a 12-month low of $0.59 and a 12-month high of $9.99. The stock’s fifty day simple moving average is $0.89 and its 200-day simple moving average is $1.03.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.